Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ptc Therapeutics (NQ: PTCT ) 43.18 +2.31 (+5.65%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ptc Therapeutics < Previous 1 2 3 4 5 6 Next > Earnings Preview For PTC Therapeutics November 06, 2024 Via Benzinga 3 Top Stocks That Could Still Rocket Higher in 2024 October 04, 2024 Upcoming Food and Drug Administration decisions could push these stocks through the roof. Via The Motley Fool PTC Therapeutics Stock Earns RS Rating Upgrade To 83 August 19, 2024 The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83. Via Investor's Business Daily PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024 August 08, 2024 PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. Via InvestorPlace PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 10, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Recap: PTC Therapeutics Q4 Earnings February 29, 2024 Via Benzinga Earnings Scheduled For February 29, 2024 February 29, 2024 Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. Via Benzinga Earnings Preview: PTC Therapeutics February 28, 2024 Via Benzinga Analyst Expectations for PTC Therapeutics's Future November 20, 2023 Via Benzinga PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings July 03, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 28, 2024 Via Benzinga PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again June 28, 2024 The company plans to ask for another re-examination for its drug in Europe. Via Investor's Business Daily Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday June 21, 2024 Via Benzinga PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder June 20, 2024 PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program. Via Benzinga Exposures Product Safety The 3 Most Undervalued Biotech Stocks to Buy in June 2024 June 04, 2024 https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate Via InvestorPlace Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 20, 2024 Via Benzinga European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance May 20, 2024 PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available... Via Benzinga Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday May 20, 2024 Via Benzinga PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' May 20, 2024 The EC is asking its committee to reexamine its decision on Translarna. Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's Pre-Market Session May 20, 2024 Via Benzinga PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 May 01, 2024 PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72. Via Investor's Business Daily PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 April 25, 2024 PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities 1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? February 11, 2024 Bad news for one player does not always equal good news for another. Via The Motley Fool PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug January 26, 2024 European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market. Via Investor's Business Daily PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe January 26, 2024 CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment. Via Benzinga 12 Health Care Stocks Moving In Friday's Pre-Market Session January 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session January 25, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session October 27, 2023 Via Benzinga Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? October 27, 2023 In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
